What's the treatment plan in this case
Reading File
Searching PubMed
gastric cancer peritoneal metastasis treatment chemotherapy
Finding Sources
Searching PubMed
metastatic gastric cancer first line chemotherapy FLOT FOLFOX nivolumab
Searching the Web
Stage IV gastric cancer peritoneal metastasis treatment guidelines 2024 2025 NCCN ESMO
Finding Sources
Reading Web Page
metastatic gastric cancer peritoneal metastasis first line treatment chemotherapy immunotherapy
Finding Sources
Searching the Web
gastric cancer peritoneal carcinomatosis staging laparoscopy positive treatment FLOT nivolumab pembrolizumab 2025
Reading File
Reading Web Page
metastatic gastric cancer peritoneal carcinomatosis treatment palliative chemotherapy NCCN 2025
Reading File
I now have enough information to give a thorough, guideline-based answer. Let me compile the full treatment plan.
Case Summary
Patient: Mr. Banda Srinivas, 51M
Diagnosis: Carcinoma Stomach - moderately to poorly differentiated adenocarcinoma with focal signet ring cell features
Comorbidity: Diabetes mellitus (ECOG PS 1)
Staging findings (Laparoscopy + PET-CT = Stage IV / M1):
- Circumferential gastric wall involvement (fundus + body)
- Perilesional fat stranding abutting left liver lobe, left crus of diaphragm, body of pancreas
- Multiple perilesional lymph nodes (involved)
- Laparoscopy confirmed: visceral peritoneal deposits, multiple omental nodules (greater omentum adherent to stomach along greater curvature), subdiaphragmatic peritoneal nodularity
- No ascites, liver grossly normal
Key conclusion: This is Stage IV gastric adenocarcinoma with confirmed peritoneal metastasis (carcinomatosis), likely a high peritoneal cancer index given the extent of omental involvement - making curative surgery not immediately feasible.
Treatment Plan
Immediate Priority: Biomarker Testing (Mandatory Before Starting Systemic Therapy)
Before starting any systemic therapy, the following must be sent if not already done:
| Biomarker | Why It Matters |
|---|---|
| HER2 (IHC/FISH) | If HER2 3+ or 2+/FISH+, trastuzumab is added to first-line chemo; T-DXd is an option in 2nd line |
| PD-L1 CPS (Combined Positive Score) | Nivolumab requires CPS ≥ 1; pembrolizumab requires CPS ≥ 1-10 (per 2026 FDA labeling updates) |
| MSI/MMR status | MSI-H/dMMR tumors respond dramatically to immunotherapy (nivolumab + ipilimumab or pembrolizumab monotherapy) |
| EBER (EBV) | EBV+ tumors have very high PD-L1 expression and better immunotherapy response |
| CLDN18.2 | Zolbetuximab combined with chemo is approved for CLDN18.2-positive, HER2-negative tumors |
First-Line Systemic (Palliative) Chemotherapy
This patient is not immediately resectable due to peritoneal disease burden. The goal is systemic disease control first, with reassessment.
HER2-Negative Disease (most likely given diffuse/signet ring histology):
Preferred backbone: FOLFOX or XELOX (CapeOX)
- Oxaliplatin 130 mg/m² D1 + Capecitabine 1000 mg/m² BID D1-14, q3w (XELOX/CapeOX) - easier in outpatient setting
- OR: Oxaliplatin 85 mg/m² + Leucovorin + 5-FU (FOLFOX) q2w
Add immunotherapy based on biomarkers:
- If PD-L1 CPS ≥ 5: Add Nivolumab 360 mg q3w (CheckMate 649 data - median OS benefit ~14 months vs ~11 months)
- If PD-L1 CPS ≥ 1: Nivolumab still an option per NCCN; pembrolizumab (KEYNOTE-859) also acceptable
- If MSI-H/dMMR: Consider nivolumab + ipilimumab (phase 2 NO LIMIT trial, 2025 - high response rates) or pembrolizumab alone
If HER2-Positive:
- Platinum/fluoropyrimidine + Trastuzumab (8 mg/kg load, then 6 mg/kg q3w) ± pembrolizumab (KEYNOTE-811 data)
If CLDN18.2-positive, HER2-negative:
- XELOX + Zolbetuximab (SPOTLIGHT/GLOW trials) - now included in NCCN as a preferred regimen
HIPEC/Cytoreductive Surgery Consideration (Peritoneal-Limited Disease Algorithm)
Per the NCCN Gastric Cancer Guidelines v2.2025, an algorithm for peritoneal-limited disease exists:
- Start systemic therapy first (minimum 3 months)
- Reassess with CT ± repeat laparoscopy after 3-6 cycles
- If disease stabilizes/responds AND peritoneal cancer index (PCI) ≤ 10 on reassessment, a multidisciplinary tumor board may consider:
- Cytoreductive surgery (CRS) + gastrectomy + HIPEC (typically cisplatin ± mitomycin C)
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is no longer recommended by NCCN (removed from 2025 updates)
This patient's case - given the extensive omental nodules and multifocal peritoneal deposits - likely has a high PCI at this point, making immediate CRS+HIPEC not appropriate. Systemic therapy first with response reassessment is the correct pathway.
Diabetes Management During Chemotherapy
- Coordinate with endocrinology/diabetologist
- Corticosteroid use (as antiemetic - dexamethasone) will worsen glycemic control - monitor closely
- Consider switching dexamethasone to lower dose or substituting with aprepitant-based antiemetic regimens to minimize steroid exposure
- Capecitabine is preferred over cisplatin in diabetics (less nephrotoxicity risk)
Supportive/Symptomatic Care
| Issue | Management |
|---|---|
| Anemia (needed PRBC transfusion) | Monitor Hb; consider ESA or periodic transfusions; treat nutritional deficiencies (iron, B12, folate) |
| Early satiety/weight loss | Nutritional support - oral supplements, dietitian referral; consider enteral feeding if oral intake insufficient |
| Gastric obstruction risk | If GOO develops - consider endoscopic stenting or surgical bypass; not a reason to attempt curative resection |
| Pain/symptom control | Proton pump inhibitor (already started: Pantoprazole 40 mg), sucralfate for mucosal protection |
| Constipation (Lactulose prescribed) | Continue bowel care during chemotherapy |
| Palliative care referral | Early palliative care integration improves QoL and may improve survival in metastatic GI cancers |
Follow-Up & Monitoring Plan
- Tumor board discussion before starting chemotherapy (multidisciplinary: surgical oncology + medical oncology + gastroenterology + radiology)
- Baseline CT chest/abdomen/pelvis before first cycle (for response comparison)
- Restaging after 3 cycles (~9 weeks) with CT ± repeat diagnostic laparoscopy if considering CRS+HIPEC
- Repeat biomarkers if tissue block available for comprehensive molecular profiling (NGS if accessible)
- Patient already instructed to return to Surgical Oncology OPD for chemotherapy initiation
Prognosis Counseling
- Median survival for Stage IV gastric cancer with peritoneal metastasis: approximately 6-12 months with chemotherapy alone; newer immunotherapy combinations have pushed this to ~14-17 months in CPS ≥ 5 subgroups
- Signet ring cell/poorly differentiated histology is an adverse prognostic feature
- Response to first-line therapy is the most important predictor of whether CRS+HIPEC will ever become an option
Bottom line for this case: The patient needs urgent multidisciplinary tumor board discussion, comprehensive biomarker testing, and initiation of XELOX (or FOLFOX) + nivolumab (if PD-L1 CPS ≥ 1) as first-line palliative systemic therapy. Surgery is deferred pending response. CRS+HIPEC remains a possibility only if the peritoneal disease responds significantly and PCI drops to ≤ 10.
References: Current Surgical Therapy 14e (Saunders/Elsevier) - Gastric Adenocarcinoma chapter | NCCN Gastric Cancer Guidelines v2.2025 (Ajani et al., JNCCN 2025, PMID 40341199) | CheckMate 649 3-year follow-up (JCO 2024) | Boshier et al. systematic review on intraperitoneal chemotherapy for gastric cancer (Eur J Surg Oncol 2025, PMID 39644811)
This is a shared conversation. Sign in to Orris to start your own chat.